$-0.32 EPS Expected for Dova Pharmaceuticals Inc (DOVA)

November 8, 2017 - By Adrian Mccoy

Wall Street await Dova Pharmaceuticals Inc (NASDAQ:DOVA) to release earnings on November, 9. After posting $-0.32 EPS for the previous quarter, Dova Pharmaceuticals Inc’s analysts now forecast 0.00 % EPS growth. The stock decreased 5.49% or $1.4 during the last trading session, reaching $24.11. About shares traded. Dova Pharmaceuticals Inc (NASDAQ:DOVA) has 0.00% since November 8, 2016 and is . It has underperformed by 16.70% the S&P500.

Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $618.48 million. The Firm is focused on acquiring, developing and commercializing drug candidates. It currently has negative earnings. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count.

More notable recent Dova Pharmaceuticals Inc (NASDAQ:DOVA) news were published by: Businesswire.com which released: “Dova Pharmaceuticals Announces Hiring of CEO and Presentation at the 35th …” on January 06, 2017, also Marketwatch.com with their article: “24.11” published on June 08, 2017, Benzinga.com published: “43% Upside Seen For Dova Pharma Following Competitor Product’s Poor Results” on September 26, 2017. More interesting news about Dova Pharmaceuticals Inc (NASDAQ:DOVA) were released by: Seekingalpha.com and their article: “Dova Pharmaceuticals: A Different Business Model Could Lead To Success” published on June 27, 2017 as well as Marketwatch.com‘s news article titled: “Dova Pharmaceuticals sets IPO terms to raise $69.1 million before options” with publication date: June 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com